These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 22923433)

  • 41. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway.
    Presneau N; Shalaby A; Idowu B; Gikas P; Cannon SR; Gout I; Diss T; Tirabosco R; Flanagan AM
    Br J Cancer; 2009 May; 100(9):1406-14. PubMed ID: 19401700
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex.
    Ebrahimi-Fakhari D; Agricola KD; Tudor C; Krueger D; Franz DN
    Pediatr Neurol; 2020 Apr; 105():59-61. PubMed ID: 31924480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.
    Meikle L; Pollizzi K; Egnor A; Kramvis I; Lane H; Sahin M; Kwiatkowski DJ
    J Neurosci; 2008 May; 28(21):5422-32. PubMed ID: 18495876
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
    Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
    Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
    [TBL] [Abstract][Full Text] [Related]  

  • 45. mTOR as a therapeutic target in patients with gastric cancer.
    Al-Batran SE; Ducreux M; Ohtsu A
    Int J Cancer; 2012 Feb; 130(3):491-6. PubMed ID: 21898386
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.
    Morrow PK; Wulf GM; Ensor J; Booser DJ; Moore JA; Flores PR; Xiong Y; Zhang S; Krop IE; Winer EP; Kindelberger DW; Coviello J; Sahin AA; Nuñez R; Hortobagyi GN; Yu D; Esteva FJ
    J Clin Oncol; 2011 Aug; 29(23):3126-32. PubMed ID: 21730275
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
    Brakemeier S; Bachmann F; Budde K
    Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tuberous sclerosis complex.
    Hasbani DM; Crino PB
    Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2.
    Kwiatkowski DJ; Palmer MR; Jozwiak S; Bissler J; Franz D; Segal S; Chen D; Sampson JR
    Eur J Hum Genet; 2015 Dec; 23(12):1665-72. PubMed ID: 25782670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report.
    Tarasewicz A; Dębska-Ślizień A; Bułanowski M; Więcek A; Rutkowski B
    Transplant Proc; 2014 Oct; 46(8):2912-5. PubMed ID: 25380949
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Somatic Mutations in TSC1 and TSC2 Cause Focal Cortical Dysplasia.
    Lim JS; Gopalappa R; Kim SH; Ramakrishna S; Lee M; Kim WI; Kim J; Park SM; Lee J; Oh JH; Kim HD; Park CH; Lee JS; Kim S; Kim DS; Han JM; Kang HC; Kim HH; Lee JH
    Am J Hum Genet; 2017 Mar; 100(3):454-472. PubMed ID: 28215400
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mammalian target of rapamycin: biological function and target for novel anticancer agents.
    Borders EB; Bivona C; Medina PJ
    Am J Health Syst Pharm; 2010 Dec; 67(24):2095-106. PubMed ID: 21116000
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tissue-specific ablation of Tsc1 in pancreatic beta-cells.
    Mori H; Guan KL
    Methods Mol Biol; 2012; 821():407-19. PubMed ID: 22125081
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.
    Witzig TE; Reeder C; Han JJ; LaPlant B; Stenson M; Tun HW; Macon W; Ansell SM; Habermann TM; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Colgan JP; Markovic S; Nowakowski GS; Gupta M
    Blood; 2015 Jul; 126(3):328-35. PubMed ID: 25921059
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.
    Chiong E; Lee IL; Dadbin A; Sabichi AL; Harris L; Urbauer D; McConkey DJ; Dickstein RJ; Cheng T; Grossman HB
    Clin Cancer Res; 2011 May; 17(9):2863-73. PubMed ID: 21415218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deficiency in pulmonary surfactant proteins in mice with fatty acid binding protein 4-Cre-mediated knockout of the tuberous sclerosis complex 1 gene.
    Xiang X; Yuan F; Zhao J; Li Z; Wang X; Guan Y; Tang C; Sun G; Li Y; Zhang W
    Exp Physiol; 2013 Mar; 98(3):830-41. PubMed ID: 23143994
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
    Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
    Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.
    Keck S; Glencer AC; Rugo HS
    Future Oncol; 2012 Nov; 8(11):1383-96. PubMed ID: 23148612
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical presentations and molecular studies of invasive renal epithelioid angiomyolipoma.
    Chuang CK; Lin HCA; Tasi HY; Lee KH; Kao Y; Chuang FL; Chang YH; Lin PH; Liu CY; Pang ST
    Int Urol Nephrol; 2017 Sep; 49(9):1527-1536. PubMed ID: 28547571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells.
    Justin S; Rutz J; Maxeiner S; Chun FK; Juengel E; Blaheta RA
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32512849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.